Ocuphire Pharma Inc expected to post a loss of 33  cents a share - Earnings Preview

Opus Genetics

08/08/2022 18:00

* Ocuphire Pharma Inc  OCUP.OQ   OCUP.O  is expected to show
a
fall in quarterly revenue when it reports  results on August 10
(estimated). 
    * ​Refinitiv's mean analyst estimate for Ocuphire Pharma Inc
is
for a loss of 33 cents per share. For the same quarter last
year, the company reported a loss of 52 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ocuphire
Pharma
Inc is $25​, above​ its last closing price of $1.91. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.34       -0.35      -0.35     Met     0
 Dec. 31 2022  -0.20       -0.29      -0.35     Missed  -22.1
 Sep. 30 2021  -0.39       -0.36      -0.25     Beat    30.2​
 Jun. 30 2021  -0.36       -0.36      -0.52     Missed  -43.1
 ​​Mar.        -0.70       -0.71      -0.47     Beat    34
 31 2021                                                
 Dec. 31 2020  -0.42       -0.42      -5.18     Missed  -1,133
                                                        .3​
                                      -0.33             
                                      -0.62             
 This summary was machine generated August 8 at 17:00 GMT.  All
figures in US dollars  unless otherwise stated